🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial Cancer

RecruitingNAAges 18 Years - anyFemaleMcGill University Health Centre/Research Institut…
NCT07871838 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Clinical experience with hypo fractionated radiotherapy to date has shown that it is a safe and effective way to treat many types of cancer. Hypo fractionation means that the patient receives a total of 5 radiation treatments every other day, rather than 25 treatments over 5 weeks. The goal of this study is to find out how safe this special kind of radiation technique is for women with endometrial cancer, both right after the treatment and later on. We also want to see how well this treatment works in stopping the cancer from coming back and how it affects the patients' overall health and quality of life. The main question it aims to answer is: How does this particular type of radiotherapy affect the patients in terms of short and long term side effects? Participants will: * Visit the clinic for a total of 15 times in 60 months for check ups * Complete a total of 9 questionnaires thr

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients 18 years of age or older, ECOG 0-2. * Newly diagnosed endometrial carcinoma, including endometrioid, serous, clear cell, carcinosarcoma, and dedifferentiated tumours. * FIGO 2009 stage I-IIIC1 are eligible. 20. * Patients will have had previous total hysterectomy + bilateral salpingo-oophorectomy + sentinel lymph node biopsy or pelvic nodal dissection, will be fully debulked (R0 resection). * Have an indication for adjuvant pelvic radiotherapy by the attending radiation oncology physician at tumour board discussion. Exclusion Criteria: * ECOG 3 or higher. * Para-aortic nodal disease. * Non-standard surgery, evidence of residual disease after surgery. * Need of a radiotherapy field exceeding the whole pelvis. * Active inflammatory bowel disease. * Active scleroderma. * Previous cancer in the last 5 years (except non-melanoma skin cancer). * Patients with contraindication to CT contrast. * Inability to achieve dose constraints. * Inability to reproduce simulation positioning during treatment.
💊

What it tests

  • Hypo fractionated RT
📍

Where

1 site
McGill University Health Centre--Cedars Cancer Centre
Montreal, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy